Among various methods for preventing ventilator-associated pneumonia (VAP), the evidence base for selective digestive decontamination (SDD) appears most compelling. However, the extent of Staphylococcus aureus emergence with SDD use remains uncertain. Groups from 37 observational studies and component (control and intervention) groups from 58 studies of SDD and other methods of VAP prevention were sourced exclusively from 10 systematic reviews. S. aureus as a proportion of VAP isolates (S. aureus isolate proportion [S. aureus IP]) among component groups was calibrated versus that among observational groups (the benchmark). The influence of topical placebo used for blinding purposes and other group-level factors was estimated using generalized estimating equation methods (GEE). The mean S. aureus IP is 22% (95% confidence interval [CI], 19 to 25) for 37 observational groups versus 32% (24 to 41) and 20% (15 to 25) for 22 control groups from the SDD evidence base which did versus did not receive topical placebo, respectively. In GEE models including all 148 observational and component groups, membership of a control (P ؍ 0.03) or intervention (P < 0.001) group of an SDD study that used topical placebo was associated with higher S. aureus IP, whereas, in contrast, membership of these groups was without effect on Pseudomonas aeruginosa. Topical placebo is implicated as a vehicle for selective cross-infection with S. aureus within the specific context of the SDD evidence base. This effect of topical placebo is perfidious; it could contribute to the higher VAP incidence and inflate the apparent "effectiveness" of SDD. The SDD evidence base requires reappraisal. Selective digestive decontamination (SDD), an extensively studied method for VAP prevention (9, 10), achieves decreased colonization with aerobic Gram-negative bacilli at the oropharynx (11) through the use of topical antibiotic paste. However, SDD may increase colonization with Gram-positive bacteria (12, 13), including staphylococci (14, 15).The SDD evidence base is unusual in four respects. The mean VAP incidence in the concurrent control groups of SDD studies is more than 10 percentage points higher, and the dispersion is greater, than a benchmark of VAP incidence proportion (VAP-IP) derived from observational studies and also versus control groups of studies of other strategies of VAP prevention using nonantibiotic methods (16). Strikingly, the disparity versus this benchmark is even greater for control groups from SDD studies rated as higher in study quality as a consequence of observer blinding achieved by the use of topical placebo (17). Paradoxically, the VAP incidence of the intervention groups within the SDD evidence base is more homogeneous, and the mean is within less than 10 percentage points of the VAP incidence benchmark (17). Finally, the explanation for the profound difference in VAP incidence seen between intervention and control groups of SDD studies is unclear. Specifically, an antipseudomonal activity of SDD is not evident within the lis...